Narayana Hrudayalaya Ltd. has informed the Exchange about Scheme of Arrangement - Receipt of Observation Letters with "No Adverse Observations" from BSE Limited in relation to Scheme of Arrangement between Meridian Medical Research & Hospital Ltd (Transferor Company) and Narayana Hrudayalaya Limited (Transferee Company).
NH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts more than Nifty Smallcap 250 and 3.3 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Narayana Hrudayalaya Ltd. (NHL) has received a 'No Adverse Observations' letter from BSE Limited on June 23, 2025, for its proposed Scheme of Arrangement with its subsidiary Meridian Medical Research & Hospital Ltd. (MMRHL). Under the scheme, MMRHL (Transferor Company) will merge into NHL (Transferee Company) under Sections 230-232 of the Companies Act, 2013. The board had originally approved this scheme on November 29, 2024. SEBI had also issued its comments on the scheme earlier on June 20, 2025. The observation letter is valid for six months, within which the company must file the scheme with the National Company Law Tribunal (NCLT). Several disclosure and compliance requirements have been laid out by BSE/SEBI before the scheme can proceed to NCLT and then to shareholders and creditors for approval.
This is a procedural regulatory milestone and not directly price-moving. For shareholders, the scheme would consolidate MMRHL (a subsidiary) fully into NHL, simplifying the group structure. Shareholders should wait for the share swap ratio announcement and NCLT approval before assessing any real impact on their holdings.